Cutler Group LP Akebia Therapeutics, Inc. Transaction History

Cutler Group LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 25, 2022	BUY	$0.3 - $0.46 $960 - $1,472	3,200 Added 1600.0%	3,400 $1,000
Q2 2022 Aug 04, 2022	BUY	$0.32 - $0.67 $64 - $134	200 New	200 $0
Q4 2021 Jan 18, 2022	SELL	$2.26 - $3.34 $1,581 - $2,338	-700 Closed	0 $0
Q4 2020 Jan 21, 2021	BUY	$2.22 - $3.78 $157 - $268	71 Added 11.29%	700 $1,000
Q4 2017 Jan 17, 2018	SELL	$14.24 - $19.59 $256,903 - $353,423	-18,041 Reduced 96.63%	629 $9,000
Q3 2017 Oct 17, 2017	BUY	$13.06 - $19.67 $243,830 - $367,238	18,670	18,670 $367,000

120

54.9M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $417M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.